Researchers have found the first evidence in human ovarian tissue that exposure to ibuprofen during the crucial first three months of foetal development results in a "dramatic loss" of the germ cells that go into making the follicles from which female eggs develop.
The germ cells either die or fail to grow and multiply at the usual rate.
"We found that two to seven days of exposure to ibuprofen dramatically reduced the germ cell stockpile in human foetal ovaries during the first trimester of pregnancy and the ovaries did not recover fully from this damage," said Severine Mazaud-Guittot, from the National Institute of Health and Medical Research in France.
Around 30 per cent of women are estimated to use ibuprofen in the first three months of pregnancy.
Current recommendations are that the pain killer should not be taken after that time as it is known to increase the risks of foetal malformations. However, there is no firm guidance on whether or not it is safe to take in the early weeks.
For the study, published in the journal Human Reproduction, the researchers obtained human foetuses between 7-12 weeks of development from legally induced terminations of pregnancy and with the mothers' consent.
In addition, the researchers measured the quantity of ibuprofen in the blood in the umbilical cord in order to analyse how much the foetus would have been exposed to.
They found that ibuprofen crosses the placental barrier.
"This is the first study to look at the effects of ibuprofen on the ovarian tissue of baby girls, and the first to show that ibuprofen can cross the placental barrier during the first trimester of pregnancy, exposing the foetus to the drug," said Mazaud-Guittot.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
